B-cell study for giant cell arteritis and related conditions
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study looks at immune cells called B-cells in people with giant cell arteritis (a condition causing inflammation in blood vessels) and other immune disorders, to see if targeting these cells could be a new treatment. It involves imaging and blood tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older and have giant cell arteritis, or you are 18 or older with a B-cell mediated immune disorder, or you are 50 or older with an aortic aneurysm.
- For giant cell arteritis: you must meet the 2022 classification criteria and have imaging evidence of active large-vessel inflammation in the last 4 weeks.
- You are planning to be treated with corticosteroids only (for the GCA group) or standard care (for other groups).
- You have not been on corticosteroids for more than 4 weeks before the start of the study.
- You do not have severe kidney problems, are not pregnant or breastfeeding, and can give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug tocilizumab (Actemra) to see if it helps reduce swelling in the aorta in people with giant cell arteritis (GCA) who are newly diagnosed or have had a flare. It may offer a targeted treatment for aortitis without using high-dose steroids.
This study uses ultrasound, a biopsy of the temple artery, and blood tests to improve how giant cell arteritis (GCA) is diagnosed, monitored, and predicted. It may help doctors find better ways to manage this condition.
This trial tests a medicine called upadacitinib (an anti-JAK pill) for people with giant cell arteritis that affects the large arteries, especially the aorta. It is for those whose disease is active despite trying another treatment called tocilizumab, and aims to reduce inflammation and prevent damage.
This study tracks patients with giant cell arteritis (GCA, a blood vessel inflammation affecting older adults) who are in remission and tapering their steroid medications. Researchers will monitor disease activity through blood tests and patient questionnaires to understand if their condition stays stable as they reduce treatment.
This trial tests whether a drug called bosentan, which is usually used for other conditions, can help calm the inflammation in giant cell arteritis and reduce symptoms. You would take it in addition to your usual treatment, and it might help lower the dose of steroids you need.
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
Hear when a new Giant Cell Arteritis (GCA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.